This decision tree model estimates the cost per response and incremental cost per additional responder for romiplostim, eltrombopag, and “watch and rescue” for immune thrombocytopenia.
Melissa Eisen, MD
Advertisement
Articles by Melissa Eisen, MD
Advertisement
Latest Updated Articles
- Cost Per Response Analysis of Strategies for Chronic Immune Thrombocytopenia
Published: July 11th 2018 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
A "One-Two Punch" to Innovation? The Most Favored Nation Order and Broader US Drug Pricing Reform
2
Telemedicine Boosts Quality of Life, Inhaler Technique for Severe COPD
3
Bispecific Antibodies in Multiple Myeloma Are Moving From Clinical Trials to Community Practice
4
White House to Announce Second Drug Pricing Deal as AstraZeneca Joins TrumpRx
5
